-
Bharat Biotech’s Covaxin recommended by expert panel for phase 2/3 trials on 2-18 year-olds
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur
-
Delhi asks Centre to share vaccine formula to raise production
As many as 125 centres administering Covaxin to 18-44 age group are likely to be closed down by Wednesday as the Delhi government did not receive new
-
Andhra Pradesh govt to float global tender soon for procurement of Covid vaccines
The state has identified 2.04 crore people in the 18- 45 age group for whom the Covid-19 vaccine has to be administered
-
GST on vaccines: A curious stance on pricing freedom
While the Centre has adopted a hands-free approach to vaccine pricing it has been hands-on in industrial policy with import duty hikes, incentives for
-
Money9 Edit | Bots eating up vaccine slots
The need for these bots and their efficiency come into play with citizens finding it virtually impossible to find slots on the official government app
-
GST on vaccines – an unnecessary controversy?
COVID – 19 vaccines certainly do meet the criteria for an exemption. However, the same cannot be granted for various reasons.
-
Budget heading for jab expenditure does not inhibit Centre from using funds: FinMin
Since expenditure on vaccine is one-off expenditure outside the normal Centrally-Sponsored Schemes of the health ministry, separate funding ensures ea
-
Government in Supreme Court rules out door-to-door COVID vaccination
The government said inoculation will be done at identified COVID Vaccination Centres, both government and private, registered on COWIN for "good, germ
-
India’s Coronavirus battle stokes vaccine worries in Africa
Lacking the means to manufacture their own vaccine in bulk, African countries have so far had to turn to the open market or the Covax scheme
-
Vaccine strategy: Centre urges against ‘overzealous’ judicial intervention
Vaccination of the entire country is not possible in one stretch due to the very suddenness of the pandemic and limited availability of vaccine doses,
